Revance Therapeutics, Inc. (NASDAQ:RVNC) Position Trimmed by Centaurus Financial Inc.

Centaurus Financial Inc. lessened its holdings in shares of Revance Therapeutics, Inc. (NASDAQ:RVNC) by 28.2% during the 4th quarter, HoldingsChannel reports. The fund owned 17,612 shares of the biopharmaceutical company’s stock after selling 6,915 shares during the period. Centaurus Financial Inc.’s holdings in Revance Therapeutics were worth $155,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently bought and sold shares of RVNC. Rubric Capital Management LP purchased a new position in Revance Therapeutics during the 3rd quarter valued at about $18,352,000. Invesco Ltd. grew its stake in shares of Revance Therapeutics by 66.0% in the 3rd quarter. Invesco Ltd. now owns 2,902,440 shares of the biopharmaceutical company’s stock valued at $33,291,000 after buying an additional 1,153,615 shares in the last quarter. CIBC Asset Management Inc grew its stake in shares of Revance Therapeutics by 251.2% in the 4th quarter. CIBC Asset Management Inc now owns 1,147,294 shares of the biopharmaceutical company’s stock valued at $10,085,000 after buying an additional 820,587 shares in the last quarter. EULAV Asset Management grew its stake in shares of Revance Therapeutics by 275.0% in the 3rd quarter. EULAV Asset Management now owns 600,000 shares of the biopharmaceutical company’s stock valued at $6,882,000 after buying an additional 440,000 shares in the last quarter. Finally, DCF Advisers LLC grew its stake in shares of Revance Therapeutics by 869.3% in the 4th quarter. DCF Advisers LLC now owns 256,872 shares of the biopharmaceutical company’s stock valued at $2,258,000 after buying an additional 230,372 shares in the last quarter. Hedge funds and other institutional investors own 97.70% of the company’s stock.

Analyst Ratings Changes

RVNC has been the subject of several recent research reports. Piper Sandler reissued an “overweight” rating and issued a $11.00 price target (down previously from $20.00) on shares of Revance Therapeutics in a research note on Friday, May 10th. Mizuho lowered their price target on Revance Therapeutics from $9.00 to $8.00 and set a “neutral” rating for the company in a research note on Friday, May 10th. The Goldman Sachs Group reduced their target price on Revance Therapeutics from $9.00 to $8.00 and set a “neutral” rating for the company in a report on Monday, May 13th. Needham & Company LLC reduced their target price on Revance Therapeutics from $18.00 to $12.00 and set a “buy” rating for the company in a report on Friday, May 10th. Finally, HC Wainwright reduced their target price on Revance Therapeutics from $12.00 to $11.00 and set a “buy” rating for the company in a report on Monday, May 13th. Five research analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus price target of $11.50.

Revance Therapeutics Price Performance

Shares of RVNC stock opened at $2.80 on Wednesday. Revance Therapeutics, Inc. has a 12 month low of $2.57 and a 12 month high of $29.43. The firm has a market cap of $292.46 million, a PE ratio of -0.77 and a beta of 1.05. The stock has a 50 day moving average of $3.36 and a 200-day moving average of $5.26.

Revance Therapeutics (NASDAQ:RVNC) last issued its quarterly earnings results on Thursday, May 9th. The biopharmaceutical company reported ($0.54) EPS for the quarter, topping analysts’ consensus estimates of ($0.66) by $0.12. The business had revenue of $51.94 million for the quarter, compared to analyst estimates of $55.64 million. As a group, equities analysts predict that Revance Therapeutics, Inc. will post -1.83 EPS for the current fiscal year.

Revance Therapeutics Company Profile

Revance Therapeutics, Inc, a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company's lead drug candidate is DAXXIFY (DaxibotulinumtoxinA-lanm) for injection for the treatment of glabellar lines and cervical dystonia; has completed phase II clinical trials to treat upper facial lines, moderate or severe dynamic forehead lines, and moderate or severe lateral canthal lines; and has completed Phase II clinical trials for the treatment of adult upper limb spasticity and plantar fasciitis.